Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AGFA HealthCare Puts Clinical Attention at the Center of Enterprise Imaging at RSNA 202614.9.2026 16:30:00 CEST | Press release
One unified Enterprise Imaging platform brings workflow, streaming, cloud, and AI together to help clinicians stay focused and imaging organizations reduce complexity. CARLSTADT, NJ / ACCESS Newswire / September 14, 2026 / "Clinical attention has become one of healthcare's most valuable resources. The technology surrounding clinicians should preserve focus, not compete for it," said Nathalie McCaughley, President, AGFA HealthCare. "At RSNA 2026, we're showing how Enterprise Imaging continues to evolve around one consistent clinical experience. By bringing workflow, intelligence, and information together around how clinicians naturally work, we can reduce friction and help keep clinical attention where it matters most." At RSNA 2026, AGFA HealthCare will demonstrate how a unified approach to Enterprise Imaging can help healthcare organizations address a growing challenge: imaging volumes and clinical complexity continue to increase, while radiologists and imaging teams are being asked t
Litum Expands PathAware from Collision Warning to Forklift Safety Intelligence14.9.2026 08:00:00 CEST | Press release
PathAware® now turns collision risks, near misses and operator activity into actionable safety intelligence, while adding operator control, digital inspections and utilization insights, all through a retrofit system built for mixed forklift fleets. BOSTON, MA / ACCESS Newswire / September 14, 2026 / Litum today announced PathAware® IQ and PathAware® IQ+, expanding its forklift collision warning technology into a connected safety intelligence platform. PathAware IQ not only warns operators when risks occur. It captures safety events across the fleet and turns them into visual dashboards and actionable data, giving safety teams visibility into recurring risks, near misses, operators, vehicles, areas and shifts. This allows organizations to move from reacting to incidents to identifying patterns earlier, targeting operator training, addressing recurring hazards and measuring whether safety actions are actually working. PathAware IQ+ builds on that intelligence with digital pre-operation i
Surmodics Opens Medical Device Coating Capabilities in Ireland10.9.2026 16:00:00 CEST | Press release
The Galway Facility Brings Nearly 50 Years of Coating Expertise, Cleanroom Coating Services and Analytical Testing Closer to Medical Device Manufacturers Across Ireland and Europe BALLINASLOE, COUNTY GALWAY, IRELAND / ACCESS Newswire / September 10, 2026 / Surmodics, Inc. today announced its expanded medical device coating capabilities in Galway, Ireland, expanding access to the company's Performance Coatings and coating services for medical device manufacturers throughout Ireland and Europe. The facility now includes dedicated cleanroom environments designed for medical device coating services and brings Surmodics' nearly 50 years of coating experience closer to one of the world's leading medical technology hubs. "Ireland is home to a significant concentration of medical device manufacturers and technology innovators, making it an important market for Surmodics and our customers," said Damien Kilcommons, Vice President of Site Operation at the Ireland facility. "By establishing dedica
MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 202610.9.2026 15:20:00 CEST | Press release
New modular approach will bring together MicroVision lidar hardware, perception software and open sensor integration to enable flexible perception solutions across applications REDMOND, WA AND HANOVER, GER / ACCESS Newswire / September 10, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception technologies, today announced plans to unveil its MicroVision Perception Platform™ at IAA Transportation 2026 in Hanover, Germany next week, marking the next evolution of the company's Lidar 2.0 strategy. The new modular platform is designed to bring together MicroVision's expanding portfolio of lidar hardware, perception software and open sensor integration into a flexible architecture that can be configured around the requirements of individual applications spanning automotive, commercial vehicles, industrial, security, defense and aerial use cases. Rather than relying on a fixed sensor configuration or closed "black box" solution, the MicroVision Perception Platform is being d
GA-ASI Unveils Wildfire UAS for Military, Civil and Commercial Roles10.9.2026 15:00:00 CEST | Press release
New Uncrewed Aircraft Combines Exceptional Endurance and Range with Unsurpassed Payload and Affordability at Scale SAN DIEGO, CA / ACCESS Newswire / September 10, 2026 / The world leader in Uncrewed Aircraft Systems, General Atomics Aeronautical Systems, Inc. (GA-ASI) is pleased to announce its groundbreaking Wildfire UAS, a clean-sheet aircraft designed to maximize future investments in large uncrewed aircraft that incorporates lessons learned over decades of large-scale global UAS operations. Wildfire draws upon more than 30 years of delivering more than 1,600 world-changing uncrewed aircraft, including the MQ-1B Predator®, MQ-9A Reaper®, MQ-9B SkyGuardian®, MQ-20 Avenger® and FQ-42A Collaborative Combat Aircraft. GA-ASI aircraft have amassed nearly 10 million total flight hours, mostly in combat, and introduced many of the technologies and concepts now emulated by others around the world. "This is exactly the right design for high-demand missions and cost-conscious customers," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom